Cargando…

Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study

OBJECTIVE: This study aimed to identify determinants of immunological recovery following highly active antiretroviral therapy (HAART) among severely immunosuppressed patients at enrolment to care in Northern Ethiopia. METHODS: A retrospective study. SETTING: The study was done in Tigray Region, Nort...

Descripción completa

Detalles Bibliográficos
Autores principales: Desta, Abraham Aregay, Kidane, Kibriti Mehari, Bahta, Yemane Weldu, Ajemu, Kiros Fenta, Woldegebriel, Ataklti Gebretsadik, Berhe, Asfawosen Aregay, Bezabih, Nega Mamo, Woldu, Awtachew Berhe, Woldearegay, Tewolde Wubayehu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462238/
https://www.ncbi.nlm.nih.gov/pubmed/32868365
http://dx.doi.org/10.1136/bmjopen-2020-038741
_version_ 1783576877528514560
author Desta, Abraham Aregay
Kidane, Kibriti Mehari
Bahta, Yemane Weldu
Ajemu, Kiros Fenta
Woldegebriel, Ataklti Gebretsadik
Berhe, Asfawosen Aregay
Bezabih, Nega Mamo
Woldu, Awtachew Berhe
Woldearegay, Tewolde Wubayehu
author_facet Desta, Abraham Aregay
Kidane, Kibriti Mehari
Bahta, Yemane Weldu
Ajemu, Kiros Fenta
Woldegebriel, Ataklti Gebretsadik
Berhe, Asfawosen Aregay
Bezabih, Nega Mamo
Woldu, Awtachew Berhe
Woldearegay, Tewolde Wubayehu
author_sort Desta, Abraham Aregay
collection PubMed
description OBJECTIVE: This study aimed to identify determinants of immunological recovery following highly active antiretroviral therapy (HAART) among severely immunosuppressed patients at enrolment to care in Northern Ethiopia. METHODS: A retrospective study. SETTING: The study was done in Tigray Region, Northern Ethiopia. PARTICIPANTS: The study was done among severely immunosuppressed (<200 CD4 cells/mm(3)) individuals at initial enrolment to care and whose samples were sent for viral load determination from April 2015 to March 2019 in Tigray Health Research Institute. MAIN OUTCOMES: The main outcome variable was immunological recovery, modelled using binary logistic regression. RESULTS: Among the 9687 patients with severe immunosuppression at enrolment, 2746 (28.35%, 95% CI 27.45% to 29.26%) had immunological recovery following HAART for at least 6 months. Male gender (adjusted OR (AOR)=0.50, p<0.001), age 20–34 years old (AOR=0.33, p<0.001), age ≥50 years old (AOR=0.26, p<0.001), WHO clinical stage III (OR=0.68, p=0.036) and viral non-suppression (AOR=0.38, p<0.001) were strong predictors of immunological failure. CONCLUSIONS: Immunological recovery following HAART was low among severely immunosuppressed individuals at enrolment to care. Gender, age, WHO stage III and viral non-suppression were determinants of immunological recovery. Male patients, adolescents and virally non-suppressed patients should be identified as groups at higher risk for immunological failure. Therefore, greater support and intensive counselling should be prioritised among adolescents, men and virally non-suppressed patients for better immunological recovery.
format Online
Article
Text
id pubmed-7462238
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74622382020-09-11 Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study Desta, Abraham Aregay Kidane, Kibriti Mehari Bahta, Yemane Weldu Ajemu, Kiros Fenta Woldegebriel, Ataklti Gebretsadik Berhe, Asfawosen Aregay Bezabih, Nega Mamo Woldu, Awtachew Berhe Woldearegay, Tewolde Wubayehu BMJ Open Immunology (Including Allergy) OBJECTIVE: This study aimed to identify determinants of immunological recovery following highly active antiretroviral therapy (HAART) among severely immunosuppressed patients at enrolment to care in Northern Ethiopia. METHODS: A retrospective study. SETTING: The study was done in Tigray Region, Northern Ethiopia. PARTICIPANTS: The study was done among severely immunosuppressed (<200 CD4 cells/mm(3)) individuals at initial enrolment to care and whose samples were sent for viral load determination from April 2015 to March 2019 in Tigray Health Research Institute. MAIN OUTCOMES: The main outcome variable was immunological recovery, modelled using binary logistic regression. RESULTS: Among the 9687 patients with severe immunosuppression at enrolment, 2746 (28.35%, 95% CI 27.45% to 29.26%) had immunological recovery following HAART for at least 6 months. Male gender (adjusted OR (AOR)=0.50, p<0.001), age 20–34 years old (AOR=0.33, p<0.001), age ≥50 years old (AOR=0.26, p<0.001), WHO clinical stage III (OR=0.68, p=0.036) and viral non-suppression (AOR=0.38, p<0.001) were strong predictors of immunological failure. CONCLUSIONS: Immunological recovery following HAART was low among severely immunosuppressed individuals at enrolment to care. Gender, age, WHO stage III and viral non-suppression were determinants of immunological recovery. Male patients, adolescents and virally non-suppressed patients should be identified as groups at higher risk for immunological failure. Therefore, greater support and intensive counselling should be prioritised among adolescents, men and virally non-suppressed patients for better immunological recovery. BMJ Publishing Group 2020-08-31 /pmc/articles/PMC7462238/ /pubmed/32868365 http://dx.doi.org/10.1136/bmjopen-2020-038741 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Immunology (Including Allergy)
Desta, Abraham Aregay
Kidane, Kibriti Mehari
Bahta, Yemane Weldu
Ajemu, Kiros Fenta
Woldegebriel, Ataklti Gebretsadik
Berhe, Asfawosen Aregay
Bezabih, Nega Mamo
Woldu, Awtachew Berhe
Woldearegay, Tewolde Wubayehu
Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study
title Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study
title_full Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study
title_fullStr Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study
title_full_unstemmed Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study
title_short Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study
title_sort determinants of immunological recovery following haart among severely immunosuppressed patients at enrolment to care in northern ethiopia: a retrospective study
topic Immunology (Including Allergy)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462238/
https://www.ncbi.nlm.nih.gov/pubmed/32868365
http://dx.doi.org/10.1136/bmjopen-2020-038741
work_keys_str_mv AT destaabrahamaregay determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT kidanekibritimehari determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT bahtayemaneweldu determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT ajemukirosfenta determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT woldegebrielatakltigebretsadik determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT berheasfawosenaregay determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT bezabihnegamamo determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT wolduawtachewberhe determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy
AT woldearegaytewoldewubayehu determinantsofimmunologicalrecoveryfollowinghaartamongseverelyimmunosuppressedpatientsatenrolmenttocareinnorthernethiopiaaretrospectivestudy